BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1901 related articles for article (PubMed ID: 27412868)

  • 1. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Results of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With Bare-Metal In-Stent Restenosis: 3-Year Follow-Up of the RIBS V Clinical Trial.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; Otaegui I; Masotti M; Zueco J; Veláquez M; Sanchís J; García-Touchard A; Lázaro-García R; Moreu J; Bethencourt A; Cuesta J; Rivero F; Cárdenas A; Gonzalo N; Jiménez-Quevedo P; Fernández C;
    JACC Cardiovasc Interv; 2016 Jun; 9(12):1246-1255. PubMed ID: 27339840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
    Alfonso F; Pérez-Vizcayno MJ; Cuesta J; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Cequier A; Velázquez M; Moreno R; Mainar V; Domínguez A; Moris C; Molina E; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández-Pérez C;
    JACC Cardiovasc Interv; 2018 May; 11(10):981-991. PubMed ID: 29798776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI Study.
    Alfonso F; Cuesta J; Pérez-Vizcayno MJ; García Del Blanco B; Rumoroso JR; Bosa F; Pérez de Prado A; Masotti M; Moreno R; Cequier A; Gutiérrez H; García Touchard A; López-Mínguez JR; Zueco J; Martí V; Velázquez M; Morís C; Bastante T; García-Guimaraes M; Rivero F; Fernández C;
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1841-1851. PubMed ID: 28866036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Efficacy of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With In-Stent Restenosis (from the RIBS IV and V Randomized Clinical Trials).
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; Masotti M; López-Minguez JR; Iñiguez A; Zueco J; Velazquez M; Cequier A; Lázaro-García R; Martí V; Moris C; Urbano-Carrillo C; Bastante T; Rivero F; Cárdenas A; Gonzalo N; Jiménez-Quevedo P; Fernández C;
    Am J Cardiol; 2016 Feb; 117(4):546-554. PubMed ID: 26725102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of Drug-Eluting Balloons for Bare-Metal and Drug-Eluting In-Stent Restenosis (from the RIBS IV and V Randomized Trials).
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Sabaté M; Zueco J; Melgares R; Hernández R; Moreno R; Domínguez A; Sanchís J; Moris C; Moreu J; Cequier A; Romaguera R; Rivero F; Cuesta J; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Am J Cardiol; 2017 Apr; 119(7):983-990. PubMed ID: 28139220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial.
    Claessen BE; Henriques JPS; Vendrik J; Boerlage-van Dijk K; van der Schaaf RJ; Meuwissen M; van Royen N; Gosselink ATM; van Wely MH; Dirkali A; Arkenbout EK; Piek JJ; Baan J
    Catheter Cardiovasc Interv; 2019 Feb; 93(2):216-221. PubMed ID: 30232824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis: The Treatment of In-Stent Restenosis Study.
    Pleva L; Kukla P; Kusnierova P; Zapletalova J; Hlinomaz O
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003316. PubMed ID: 27069104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-Eluting Balloons Versus Everolimus-Eluting Stents for In-Stent Restenosis: A Meta-Analysis of Randomized Trials.
    Elgendy IY; Mahmoud AN; Elgendy AY; Mojadidi MK; Elbadawi A; Eshtehardi P; Pérez-Vizcayno MJ; Wayangankar SA; Jneid H; David Anderson R; Alfonso F
    Cardiovasc Revasc Med; 2019 Jul; 20(7):612-618. PubMed ID: 30126824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis.
    Pleva L; Kukla P; Zapletalova J; Hlinomaz O
    BMC Cardiovasc Disord; 2017 Jun; 17(1):168. PubMed ID: 28651572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial.
    Baan J; Claessen BE; Dijk KB; Vendrik J; van der Schaaf RJ; Meuwissen M; van Royen N; Gosselink ATM; van Wely MH; Dirkali A; Arkenbout EK; de Winter RJ; Koch KT; Sjauw KD; Beijk MA; Vis MM; Wykrzykowska JJ; Piek JJ; Tijssen JGP; Henriques JPS
    JACC Cardiovasc Interv; 2018 Feb; 11(3):275-283. PubMed ID: 29413242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes after treatment of bare-metal stent restenosis with paclitaxel-coated balloon catheters or everolimus-eluting stents: 3-year follow-up of the TIS clinical study.
    Pleva L; Kukla P; Zapletalova J; Hlinomaz O
    Catheter Cardiovasc Interv; 2018 Nov; 92(6):E416-E424. PubMed ID: 30019843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-Coated Balloons versus Everolimus-Eluting Stents in Patients with In-Stent Restenosis: A Pair-Wise Meta-Analysis of Randomized Trials.
    Peng N; Liu W; Li Z; Wei J; Chen X; Wang W; Lin H
    Cardiovasc Ther; 2020; 2020():1042329. PubMed ID: 32411298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
    Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial.
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García del Blanco B; García-Touchard A; López-Minguéz JR; Benedicto A; Masotti M; Zueco J; Iñiguez A; Velázquez M; Moreno R; Mainar V; Domínguez A; Pomar F; Melgares R; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2015 Jul; 66(1):23-33. PubMed ID: 26139054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 96.